Abby Hardy, Author at BioTuesdays

Developments

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

Based on initial topline data, IVERIC bio’s (NASDAQ:ISEE) Zimura met its prespecified primary endpoint in a Phase 2b dry age-related macular degeneration (AMD) clinical trial. IVERIC’s Phase 2b trial assessed Zumira, a...

October 28, 2019

Markets

Profound Medical to begin trading on NASDAQ

Profound Medical’s (TSX:PRN; OTCQX:PRFMD) common shares have been certified for listing on The Nasdaq Stock Market, with trading slated to begin on Oct. 29 under the stock symbol “PROF.” The company’s common...

October 28, 2019

Developments

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

MacroGenics (NASDAQ:MGNX) dosed the first patient in its Phase 2/3 MAHOGANY clinical trial of margetuximab for the treatment of HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial will...

October 25, 2019

Developments

Fresenius gets FDA breakthrough device designation for hemodialysis system

Fresenius Medical Care (NYSE:FMS) received FDA breakthrough device designation for its hemodialysis system, which is being developed for the prevention of blood clotting without the use of blood thinner medication. Many...

October 24, 2019

Developments

SpringWorks Therapeutics doses first patient in Phase 2b mirdametinib trial

SpringWorks Therapeutics (NASDAQ:SWTX) dosed the first patient in its Phase 2b trial evaluating mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). NF1 is a...

October 24, 2019

Developments

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

Zosano Pharma (NASDAQ:ZSAN) has begun enrolling cluster headache patients in its Phase 2/3 study evaluating C213 for the acute treatment of cluster headache. C213 consists of the same formulation of zolmitriptan as the...

October 24, 2019

Developments

Bausch + Lomb licenses Clearside’s XIPERE for macular edema associated with uveitis

An affiliate of Bausch Health Companies (NYSE,TSX:BHC) has acquired an exclusive license for the commercialization and development of XIPERE in the U.S. and Canada from Clearside Biomedical (NASDAQ:CLSD). XIPERE is a...

October 23, 2019

Developments

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit. Dr...

October 23, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Author - Abby Hardy

IVERIC bio Zimura meets primary endpoint in Phase 2b dry AMD trial

Profound Medical to begin trading on NASDAQ

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

Fresenius gets FDA breakthrough device designation for hemodialysis system

SpringWorks Therapeutics doses first patient in Phase 2b mirdametinib trial

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

Bausch + Lomb licenses Clearside’s XIPERE for macular edema associated with uveitis

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Titan Pharma to present two Probuphine posters at conference

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Subscribe